Initial results of daratumumab + lenalidomide in frail patients: The IFM 2017-03 trial
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial - The Lancet Oncology
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
POMALYST® (pomalidomide) Treatment Option
REVLIMID® (lenalidomide) - Official Patient Website
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
![PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c492928e3f0ff31a9045ef665d1d8113a4831731/3-Figure1-1.png "PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar")
PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America | NEJM
VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma | 2 Minute Medicine
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
MAIA Study | Int'l Myeloma Foundation
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Tailored lenalidomide regimen benefits older patients with multiple myeloma
547-Lenalidomide and dexamethasone oral | eviQ
POR | Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
Lenalidomide concentration profiles over time and after dexamethasone... | Download Scientific Diagram
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
